Bladder Cancer Roundtable

Join John Sfakianos, MD, Marisa Kollmeier, MD, and Matthew Galsky, MD as they discuss bladder cancer management. The faculty break down the discussion into three parts, focusing on specific therapies and treatments, including chemotherapy, immunotherapy, combination therapies, and more.

Video 1: Chemotherapy, Immunotherapy, and Radiation Therapy

In this video, Drs. Sfakianos, Kollmeier and Galsky discuss the use of chemotherapy, immunotherapy, and radiation techniques in treating bladder cancer, as well as advances in these therapies.

Up Next

Video 1: Chemotherapy, Immunotherapy, and Radiation Therapy
Video 2: Surgical Options and Combination Therapies
Video 3: Treatment of Metastatic
Bladder Cancer

About the Panel

John Sfakianos, MD

  • Assistant Professor of Urologic Oncology
  • Icahn School of Medicine at Mount Sinai

Marisa Kollmeier, MD

  • Radiation Oncologist
  • Memorial Sloan Kettering Cancer Center

Matthew Galsky, MD

  • Professor of Medical Oncology
  • Icahn School of Medicine at Mount Sinai

Drs. Galsky, Kollmeier, and Sfakianos received a modest honorarium from Frontline Medical Communications for their participation in this roundtable.

The faculty was solely responsible for the content presented in the videos.

Disclosures

Dr. Galsky discloses that he owns stocks in Rappta Therapeutics. He is a consultant or advisor for Aileron Therapetuics, AstraZeneca, Astellas Pharma, BioMotiv, Bristol-Myers Squibb, Dendreon, Dracen, Dragonfly Therapeutics, EMD Serono Genentech, GlaxoSmithKline, Incyte, Inovio Pharmaceuticals, Janssen, Lilly, Merck, Novartis, NuMab, Pfizer, and Seattle Genetics. His institution has received research funding from AstraZeneca, Bristol-Myers Squibb, Dendreon, Genentech/Roche, Janssen Oncology, Merck, and Novartis. Dr. Galsky also has patents, royalties, or other intellectual property for methods and compositions for treating cancer and related methods.

Dr. Kollmeier has no potential conflicts of interest to disclose.

Dr. Sfakianos has no potential conflicts of interest to disclose.